TD Private Client Wealth LLC Raises Stock Position in GSK PLC Sponsored ADR $GSK

Key Points

• TD Private Client Wealth LLC increased its holdings in GSK PLC Sponsored ADR by 997.5%, acquiring 70,910 additional shares, bringing its total to 78,019 shares worth nearly $3 million.
• GSK reported quarterly earnings of $1.23 per share, surpassing the consensus estimate and showing a 1.3% year-over-year revenue increase to $10.64 billion.
• The company recently declared a quarterly dividend of $0.4206, resulting in an annualized yield of 4.2% while maintaining a dividend payout ratio of 77.78%.

TD Private Client Wealth LLC lifted its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 997.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,019 shares of the pharmaceutical company's stock after acquiring an additional 70,910 shares during the period. TD Private Client Wealth LLC's holdings in GSK were worth $2,996,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GSK. Brighton Jones LLC purchased a new stake in GSK during the 4th quarter valued at approximately $528,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of GSK during the fourth quarter worth $13,730,000. BridgePort Financial Solutions LLC purchased a new position in GSK during the fourth quarter valued at $310,000. Aegis Wealth Management LLC bought a new stake in GSK in the 4th quarter valued at $286,000. Finally, Northstar Financial Companies Inc. purchased a new stake in GSK in the 4th quarter worth $228,000. Institutional investors own 15.74% of the company's stock.

GSK Stock Down 0.9%

Shares of NYSE:GSK opened at $40.17 on Thursday. The company has a market cap of $81.73 billion, a price-to-earnings ratio of 18.60, a PEG ratio of 2.02 and a beta of 0.53. GSK PLC Sponsored ADR has a 12 month low of $31.72 and a 12 month high of $42.63. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The company has a 50-day moving average price of $39.04 and a 200 day moving average price of $38.57.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping the consensus estimate of $1.12 by $0.11. The company had revenue of $10.64 billion for the quarter, compared to analysts' expectations of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The firm's revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, equities research analysts predict that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be given a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a yield of 4.2%. GSK's dividend payout ratio (DPR) is currently 77.78%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GSK. Berenberg Bank restated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. Six analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Reduce" and a consensus target price of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.